GlaxoSmithKline PLC

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
  • TickerGSK
  • ISINGB0009252882
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom
Team Pharma

ODDO : Moderna en pointe, Sanofi/GSK en embuscade

Nous analysons ici les différences notables entre les phases 1 publiées sur le vaccin contre la COVID-19, bien qu’il soit, à ce stade, délicat de comparer une étude à une autre. Les résultats de phase 1 sont dans l’ensemble positifs en termes de sécurité (enjeu premier) mais aussi d’efficacité avec la production, pour l’ensemble, d’anticorps neutralisants. Nous croyons que les résultats de BioNtech et Moderna crédibilisent d’autant plus l’approche à ARNm. Nous maintenons notre re...

Team Pharma

ODDO : Moderna in the lead, Sanofi/GSK gaining ground

In this report we analyse the notable differences between the published results of phase I tests for COVID-19 vaccines even though, at this stage, it is difficult to compare one trial with another. Phase I results have been positive overall, in terms of both safety (primary challenge) but also efficacy, with all recording the production of neutralising antibodies. We think that the results published by BioNtech and Moderna lend even greater credibility to the mRNA approach. We ar...

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : La tendance est incertaine.

La tendance est incertaine. Les cours se sont repris, mais la tendance manque de puissance pour le moment. La prochaine résistance est à 1 625,00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : The trend is uncertain.

The trend is uncertain. Prices have recovered but the trend lacks power for the time being. The next resistance is at 1,625.00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,560.00 p. Breaking below the support at 1,318.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 560,00 p. La rupture du support à 1 318,00 p invaliderait cette tendance.

Jérôme VINERIER

Medium term view - GLAXOSMITHKLINE : The background trend is clearly bullish.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at 1,321.00 p.

GlaxoSmithKline: 1 director sold

A director at GlaxoSmithKline sold 3,332 shares at 21.055USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

Team Pharma

ODDO : Moderna en pointe, Sanofi/GSK en embuscade

Nous analysons ici les différences notables entre les phases 1 publiées sur le vaccin contre la COVID-19, bien qu’il soit, à ce stade, délicat de comparer une étude à une autre. Les résultats de phase 1 sont dans l’ensemble positifs en termes de sécurité (enjeu premier) mais aussi d’efficacité avec la production, pour l’ensemble, d’anticorps neutralisants. Nous croyons que les résultats de BioNtech et Moderna crédibilisent d’autant plus l’approche à ARNm. Nous maintenons notre re...

Team Pharma

ODDO : Moderna in the lead, Sanofi/GSK gaining ground

In this report we analyse the notable differences between the published results of phase I tests for COVID-19 vaccines even though, at this stage, it is difficult to compare one trial with another. Phase I results have been positive overall, in terms of both safety (primary challenge) but also efficacy, with all recording the production of neutralising antibodies. We think that the results published by BioNtech and Moderna lend even greater credibility to the mRNA approach. We ar...

Martial Descoutures ...
  • Sebastien Malafosse

GlaxoSmithKline : Notable slowdown in Q2, recovery expected in Q3

>Marked though not surprising trends - During trading yesterday GSK published its Q2 2020 results which were marked, like its peers, by a notable and expected slowdown in group sales. Two elements stand out in these Q2 results: inventory drawdowns and also a significant slowdown in vaccine sales, notably for Shingrix (1e19% at constant currencies), and meningitis (-29% cc). This slowdown in the vaccine franchise significantly affected the group's margin. The good news ...

Martial Descoutures ...
  • Sebastien Malafosse

GlaxoSmithKline : Un ralentissement notable au T2, un rebond attendu au T3

>Des tendances marquées sans pour autant être surprenantes - GSK publiait hier en séance ses résultats du T2 qui ont été marqués, à l’instar de ses pairs, par un ralentissement notable et attendu des ventes du groupe. Deux éléments ressortent de ce T2 : le déstockage mais aussi un ralentissement significatif du Vaccin et notamment de Shingrix (-19% tcc), et Meningitis (-29% tcc). Ce ralentissement dans la franchise Vaccin est venu sensiblement impacter la marge du gr...

Team Pharma

ODDO : The run up to the US election

>Four new decrees - On Friday, president Trump signed four new decrees aimed at reducing the price of prescription drugs in the US. The aim is notably to align the price of drugs on the US market with a list of reference countries in which the prices are significantly lower. The first decree specifically targets insulin treatments for diabetic patients. In this specific case, the discounts granted to intermediaries should be automatically applied to patients. The...

GlaxoSmithKline plc: Update to credit analysis

Our credit view of GlaxoSmithKline, principally reflecting uncertainty surrounding deleveraging in the near-term and upon the Consumer Healthcare de-merger planned in 2022.

GlaxoSmithKline plc - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc: Credit metrics will continue to remain weak in 2020 despite slightly better 2019 results

Our credit view of GSK’s 2019 results and guidance on new separation programme, leading to downward pressure on earnings and slow deleveraging potential in 2020

GlaxoSmithKline plc: Update to credit analysis

Our credit view of GlaxoSmithKline, reflecting some expected improvement in the company's credit metrics but remaining uncertainty surrounding its diversification profile

Bruno Cavalier ...
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/27/2020

After years of unrealised €/$ bullish forecasts the single currency is finally on an upward trajectory. This change of course reflects a radical shift in the perception of the political risk associated with the European Union. The starting point for the rise (17 May) corresponds, moreover to the Franco-German announcement of the stimulus plan project. The European agreement of 21 July to begin the implementation process argues in favour, in a context of an upturn in PMIs, in favour of...

Louis Boujard, CFA ...
  • Philippe Ourpatian
  • Sylvain Goyon, CFA

ODDO BHF Small & MIDCAP MORNING NEWS - 27/07/2020

Après des années de prévisions haussières de l’€/$ non réalisées, l’euro connait enfin une trajectoire ascendante. Ce changement de cap reflète une évolution radicale de la perception du risque politique associé à l’Union européenne. Le point de départ de la hausse (17 mai) correspond d’ailleurs à l’annonce franco-allemande du projet de plan de relance. L’accord européen du 21 juillet pour engager son processus de mise en œuvre milite, dans un contexte de redressement des PMI, pour le...

Bruno Cavalier ...
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 27/07/2020

Après des années de prévisions haussières de l’€/$ non réalisées, l’euro connait enfin une trajectoire ascendante. Ce changement de cap reflète une évolution radicale de la perception du risque politique associé à l’Union européenne. Le point de départ de la hausse (17 mai) correspond d’ailleurs à l’annonce franco-allemande du projet de plan de relance. L’accord européen du 21 juillet pour engager son processus de mise en œuvre milite, dans un contexte de redressement des PMI, pour le...

GLAXOSMITHKLINE PLC. loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of GLAXOSMITHKLINE PLC. (GB), active in the Pharmaceuticals industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date May 19, 2020, the closing price was GBp 1,660.60 and its potential was estimated at GBp 1,820.72.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

GlaxoSmithKline – AGM 6 May 2020

Items 2-3: Remuneration report and policy   The executive incentive is highly excessive with a maximum of 800% of base salary. The qualitative criteria count for 30% of the bonus and vest in full. There is a weak alignment between the executive remunerations, shareholder interests and GlaxoSmithKline (GSK) performance. The quantum for the year is also excessive: Emma Walmsley's 2019 remuneration corresponds to 219% of the UK median remuneration in the MSCI Europe index or 290% of the Healthcare sector median.   Item 15: Re-election of Mr. Rohner, Chair of the Remuneration committee   ECG...

Expert Corporate Governance Service (ECGS)

GlaxoSmithKline - AGM 08 May 2019

The AGM is followed by an EGM to be held at 15:30 in the same location.  AGM Item 2: Approve the Remuneration Report The remuneration structure is unsatisfactory.  The main concern is the potential for excessive incentive pay with a maximum of 850% of base salary.  In addition, the use of qualitative criteria exceeds guidelines and accelerated vesting is possible.  The quantum for the year is also considered excessive.  We recommend shareholders oppose.  EGM Item 1: To approve the transaction between GlaxoSmithKline Consumer Healthcare Holdings Ltd and Pfizer Inc The Company is seeking sha...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/05/2017

Sir Andrew Witty will be stepping down as CEO with effect from 31 March 2017 and will be succeeded by Emma Walmsley. Dr Patrick Vallance joined the Board in his role as President, R&D on 1 January 2017. Item 2: Approve the Remuneration Report. The remuneration structure is unsatisfactory. Variable remuneration has the potential to be excessive and the actual awards exceeded guidelines. Item 15: Re-appoint the Auditor. PricewaterhouseCoopers LLP (PwC) have been the Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch